Multiple clinical trials with new agents are now underway or planned for patients with regional metastases from melanoma. The appropriate design and interpretation of these and future investigations will be strengthened developing an improved understanding of the clinical characteristics and outcomes associated with molecular aberrations in this disease. This integrated analysis of BRAF and NRAS mutations, 
Introduction
The clinical management of melanoma is evolving rapidly due to improved understanding of the molecular drivers of this disease. Substitutions affecting the V600 residue of the BRAF serine-threonine kinase are the most common activating mutation detected in cutaneous melanoma patients (40-45%). ( In order to test the hypothesis that molecular markers can improve existing prognostic models, and to improve our understanding of their potential role in the pathogenesis of this disease, we determined the mutational status of BRAF and NRAS, and the protein expression of PTEN, in lymphadenectomy specimens from patients who underwent standard-of-care surgical treatment for stage IIIB/C melanoma. This study includes analysis of PTEN expression (by IHC) in a cohort of tumors that previously underwent quantitative proteomic analysis. This analysis demonstrates that only complete loss of PTEN protein expression correlates with increased expression of activation-specific markers in the PI3K-AKT pathway, thus providing a molecular rationale to guide the evaluation of PTEN expression in melanoma clinical samples.
Our subsequent analysis of BRAF, NRAS, and PTEN status in a cohort of clinically annotated lymphadenectomy specimens from patients with stage IIIB/C melanoma identifies a significant association for loss of expression of PTEN with shorter overall survival and shorter time to melanoma brain metastasis.
Methods
Patients Under an Institution Review Board-approved protocol, patients were identified who underwent standard-of-care lymphadenectomy for stage IIIB/C melanoma, for whom archival material was available, and that had clinical follow-up of at least 5 years at the date of their last imaging by CT and/or MRI scan. Log-rank testing was used to assess differences between groups. The association between PTEN status and OS and time to brain metastasis was further assessed using multivariable Cox proportional hazards regression models that included age, clinical stage, and gender.
Results

Evaluation of PTEN expression by immunohistochemistry
Previously we used reverse phase protein arrays (RPPA) to quantitatively assess protein expression levels of PTEN and PI3K-AKT pathway activation-specific markers (Table   S1 ). The rate of BRAF mutations was very similar in the melanomas from known cutaneous primaries (n=94, 47.9%) and those with no known primary tumor (n=20, 40%). Mutation status was not significantly associated with the primary tumor Breslow thickness (p=0.42) or ulceration (p=0.26). Mutation status was also not significantly associated with pathological substage (IIIB/C) (p=1.00), DDFS (p=0.34), or OS (p=0.89) (Table S1 ).
Clinical associations of PTEN expression
PTEN IHC was performed on a tissue microarray (TMA) comprised of lymph node metastases from the 136 patients (Table 1) Patients with PTEN Absent developed melanoma brain metastases (MBM) at a median of 1.8 years after stage IIIB/C diagnosis, which was significantly shorter than for patients with PTEN Not Absent (median 4.9 years, p=0.03) ( Figure 2C ). In contrast, there was no significant difference in the median time to lung (p=0.92) ( Figure 2D ), liver (p=0.52), or bone (p=0.10) metastasis (Table 2) .
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